Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Proia

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
Cell Reports|July 12, 2016
Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung CancerTim N Beck, Vladislav A Korobeynikov, Alexander E Kudinov, et al.
SLAS Discovery : Advancing Life Sciences R & D|March 29, 2021
A Method for Determining the Kinetics of Small-Molecule-Induced UbiquitinationEllen F Vieux, Roman V Agafonov, Lydia Emerson, et al.
Cancer Discovery|March 28, 2013
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancerJim Sang, Jaime Acquaviva, Julie C Friedland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
<i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1Theresa A Proia, Maneesh Singh, Richard Woessner, et al.
Molecular Cancer Therapeutics|March 31, 2021
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ InhibitionLarissa S Carnevalli, Molly A Taylor, Matthew King, et al.
Cancer Discovery|July 7, 2021
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 KnockdownNabendu Pore, Song Wu, Nathan Standifer, et al.
Scientific Reports|November 24, 2018
High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancerKeith H Jansson, John B Tucker, Lauren E Stahl, et al.
RSC Medicinal Chemistry|June 16, 2025
Synthetic chemistry enabling the discovery and development of a series of pyrazoles as HPK1 inhibitorsAnthony J Metrano, Lucas A Morrill, Gayathri Bommakanti, et al.
Journal of Medicinal Chemistry|February 10, 2025
Discovery and Optimization of Pyrazine Carboxamide AZ3246, a Selective HPK1 InhibitorJason D Shields, David Baker, Amber Y S Balazs, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Cell Reports|July 12, 2016
Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung CancerTim N Beck, Vladislav A Korobeynikov, Alexander E Kudinov, et al.
SLAS Discovery : Advancing Life Sciences R & D|March 29, 2021
A Method for Determining the Kinetics of Small-Molecule-Induced UbiquitinationEllen F Vieux, Roman V Agafonov, Lydia Emerson, et al.
Cancer Discovery|March 28, 2013
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancerJim Sang, Jaime Acquaviva, Julie C Friedland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
<i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1Theresa A Proia, Maneesh Singh, Richard Woessner, et al.
Molecular Cancer Therapeutics|March 31, 2021
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ InhibitionLarissa S Carnevalli, Molly A Taylor, Matthew King, et al.
Cancer Discovery|July 7, 2021
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 KnockdownNabendu Pore, Song Wu, Nathan Standifer, et al.
Scientific Reports|November 24, 2018
High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancerKeith H Jansson, John B Tucker, Lauren E Stahl, et al.
RSC Medicinal Chemistry|June 16, 2025
Synthetic chemistry enabling the discovery and development of a series of pyrazoles as HPK1 inhibitorsAnthony J Metrano, Lucas A Morrill, Gayathri Bommakanti, et al.
Journal of Medicinal Chemistry|February 10, 2025
Discovery and Optimization of Pyrazine Carboxamide AZ3246, a Selective HPK1 InhibitorJason D Shields, David Baker, Amber Y S Balazs, et al.
Pageof 9